Exciting Preclinical Data Shared by Molecular Partners and Orano Med at SNMMI 2024

June 11, 2024 01:00 ET

Molecular Partners AG and Orano Med have unveiled positive preclinical data for their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024. This marks a significant milestone in the development of their RDT platform.

MP0712, a 212Pb-Radio-DARPin targeting DLL3, is the first candidate of Molecular Partners’ RDT platform developed in collaboration with Orano Med. The data presented showcases a positive tumor to kidney ratio, favorable biodistribution, antitumor activity, and safety profile. Plans for a first-in-human study are underway, with initial data anticipated in 2025.

The RDT platform is also expanding with a portfolio of additional targets currently under evaluation, promising new advancements in the field of radiopharmaceutical therapy. The presentation took place at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting in Toronto, Canada.

This groundbreaking development has the potential to revolutionize treatment options for small-cell lung cancer (SCLC) and other DLL3+ neuroendocrine tumors. DLL3 is expressed in a high percentage of SCLC patients, making it a crucial target for radiopharmaceutical therapy.

The preclinical data presented at SNMMI highlighted the strong tumor uptake of 212Pb-DLL3 RDT, along with significant and durable inhibition of tumor growth. Safety results indicate a favorable profile for potential clinical use. The lead candidate, MP0712, demonstrated promising biodistribution with encouraging tumor to kidney ratios.

The collaboration between Molecular Partners and Orano Med has paved the way for innovative solutions to address unmet medical needs in cancer treatment. This partnership leverages the unique properties of DARPins and 212Pb to create highly effective and targeted therapies.

The progress made in the development of MP0712 underscores the commitment of both companies to advancing the science of radiopharmaceutical therapy. With the potential for clinical trials on the horizon, this promising therapy could offer new hope for patients facing aggressive forms of cancer.

For more information on Molecular Partners AG and Orano Med, please visit their respective websites.


**Molecular Partners AG:**
Molecular Partners AG is a clinical-stage biotech company specializing in DARPin therapeutics for challenging medical conditions. Founded in 2004, the company has made significant strides in developing innovative treatment options, particularly in the field of oncology. With a strong focus on research and development, Molecular Partners continues to collaborate with leading pharmaceutical companies to bring unique solutions to patients worldwide.

**Orano Med SAS:**
Orano Med SAS is a clinical-stage biotechnology company dedicated to developing targeted therapies against cancer using lead-212 (212Pb). With state-of-the-art facilities and a focus on innovation, Orano Med is at the forefront of Targeted Alpha-Emitter Therapy (TAT). The company’s commitment to advancing cancer treatment through cutting-edge research and development positions it as a key player in the field of oncology.